Inhibition of blood platelet aggregation
AssigneeE. R. Squibb & Sons, Inc.
InventorsDon Navarro Harris, Marie B. Phillips, Harold Jacob Goldenberg
Life of this patent
Estimating the term…
Abstract
The activity of PGE.sub.1 in inhibiting aggregation of blood platelets is enhanced by employing PGE.sub.1 in combination with certain inhibitors of cyclic 3',5'-adenosine monophosphate phosphodiesterase (PDE).
Claims7
A method of inhibiting aggregation of human blood platelets which comprises contacting the platelets with PGE.sub.1 and a compound which potentiates the effectiveness of PGE.sub.1, which compound is a member selected from the group consisting of
- 4-(Butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid, ethyl ester
- 4-Chloro-1-ethyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-acetonitrile
- 1-Ethyl-4-(isopropylidenehydrazino)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-c arboxylic acid, ethyl ester, or its hydrochloride, hemihydrate
- 3-Ethyl-7,12-dimethylpyrazolo[4',3':5,6]pyrido[4,3-b]-[1,5]benzodiazepin-6- (3H)-one
- 3-Ethyl-7,12-dihydro-9-methoxy-7,12-dimethylpyrazolo[3',4':2,3]pyrido[4,5-b ][1,5]benzodiazepin-6(3H)-one
- 4-(Butylamino)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid, ethyl ester
- 4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo-[3,4-e]pyrazolo[3,4-b] pyridin-5-one
- 10-Chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo-[4',3':5,6]pyrido[4,3- b][1,5]benzodiazepin-6(3H)-one, said PGE.sub.1 being present in a concentration of from about 10.sup.-6 molar to about 10.sup.-9 molar, and said compound being present in a concentration of from about 0.1 mM to about 4 mM.
A composition for inhibiting aggregation of human blood platelets which comprises PGE.sub.1 and a member which potentiates the effectiveness of PGE.sub.1, which member is selected from the group consisting of
- 4-(Butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid, ethyl ester
- 4-Chloro-1-ethyl-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-acetonitrile
- 1-Ethyl-4-(isopropylidenehydrazino)-3-methyl-1H-pyrazolo[3,4-b]pyridine-5-c arboxylic acid, ester, or its hydrochloride, hemihydrate
- 3-Ethyl-7,12-dimethylpyrazolo[4',3':5,6]pyrido[4,3-b]-[1,5]benzodiazepin-6- (3H)-one
- 3-Ethyl-7,12-dihydro-9-methoxy-7,12-dimethyl-pyrazolo[3',4':2,3]pyrido [4,5-b][1,5]benzodiazepin-6(3H)-one
- 4-(Butylamino)-1H-pyrazolo[3,4-b]pyridine-6-carboxylic acid, ethyl ester
- 4-(Butylamino)-1-ethyl-1,7-dihydro-7-hydroxy-5H-furo[3,4-e]pyrazolo[3,4-b]p yridin-5-one
- 10-Chloro-3-ethyl-7,12-dimethyl-7,12-dihydropyrazolo-[4',3':5,6]pyrido[4,3- b][1,5]benzodiazepin-6(3H)-one, said PGE.sub.1 being present in a concentration of from about 10.sup.-6 molar to about 10.sup.-9 molar, and said member being present in a concentration of from about 0.1 mM to about 4 mM
Dependencies are inferred from the claim text.